CHEK1 and pulmonary arterial hypertension: The CHK1 inhibitor MK8776, previously tested for clinical efficacy, improved hemodynamic parameters, and attenuated vascular remodeling in an experimental model of pulmonary artery hypertension,274 suggesting a therapeutic potential for CHK1 inhibitors in the management of pulmonary artery hypertension.